Thus, the high-risk phenotype in TULIP—rather than in OptiFiT—is strongly dominated by patients with secretion deficit (with or without additional insulin-resistant NAFLD). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.